Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluering af Paro, en terapeutisk assistentrobot i analgesisk behandling under placering af en perifer intravenøs kateter hos spædbørn og børn. (PARO)

11. maj 2026 opdateret af: Fondation Lenval

Evaluering af Paro, en terapeutisk assistentrobot i analgesisk håndtering under placering af en perifer intravenøs kateter hos spædbørn og børn, et multicenter, randomiseret, prospektivt studie.

Perifer intravenøs kateterisering er en af de hyppigst udførte procedurer hos børn på skadestuer og børneafdelinger. Det forårsager ofte angst for både barnet og dets forældre, hvilket forstærker smerten forbundet med selve indgrebet, da frygt og smerte er tæt forbundet. Håndtering af barnets smerte og angst er afgørende for at optimere barnets trivsel på kort, mellemlang og lang sigt.

Kvaliteten af børneanalgesi afhænger i høj grad af den multimodale tilgang til interventioner, der tilbydes børn i smerte. For nylig er flere ikke-farmakologiske terapier til smertehåndtering og angstreduktion blevet udviklet. Blandt disse teknikker er nye teknologier opstået, såsom terapeutiske assistencerobotter udstyret med kunstig intelligens, men deres terapeutiske fordele skal stadig vurderes.

Forskerne ønsker derfor at gennemføre en undersøgelse af PARO, en terapeutisk assistencerobot formet som en babysæl, for at evaluere dens rolle i smertehåndtering under perifer venekateterisering hos børn. Forskerne agter at sammenligne de terapeutiske effekter af PARO kombineret med standardteknikker versus standardteknikker alene under smertefulde procedurer. Målet er at afgøre, om brugen af denne terapeutiske assistencerobot kan forbedre og optimere den samlede håndtering af børn, der gennemgår nåleinduceret hudpunktering. Således planlægger forskerne en multicentrisk, randomiseret, åben, overlegenhedsundersøgelse gennemført i fem børnecentre. Forskerne sigter mod at rekruttere 120 spædbørn og børn i alderen 12 måneder til 7 år, som skal gennemgå perifer venekateterisering. Smerte vil blive vurderet ved hjælp af FLACC-skalaen (Face-Legs-Activity-Cry-Consolability) i denne aldersgruppe.

Sekundære mål omfatter vurdering og sammenligning af distress i de to grupper ved hjælp af PRIC-værktøjet (Procedural Restraint Intensity for Children), som måler begrænsningsintensitet, samt overvågning af hjertefrekvensvariabilitet, antallet af forsøg, der kræves for at gennemføre proceduren, forældreangst via STAI-spørgeskemaet (State-Trait Anxiety Inventory), og endelig tilfredsheden hos både forældre og paramedicinsk personale.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

120

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

      • Brest, Frankrig
        • Ikke rekrutterer endnu
        • CHU Morvan
        • Kontakt:
      • Grasse, Frankrig
        • Ikke rekrutterer endnu
        • Centre hospitaliers de Grasse
        • Kontakt:
      • Nice, Frankrig
        • Rekruttering
        • CHU de Nice
        • Kontakt:
      • Nice, Frankrig, 06000
        • Rekruttering
        • Fondation Lenval Hôpitaux pédiatrique Nice CHU Lenval
        • Kontakt:
        • Ledende efterforsker:
          • Barabra LE GALLO, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn

Tager imod sunde frivillige

Ingen

Beskrivelse

Inklusionskriterier:

  1. er mellem 12 måneder og 7 år gamle
  2. kræver perifer intravenøs kateterisering (PIC)
  3. taler og forstår fransk.

Eksklusionskriterier:

  1. behov for kontaktisolation inklusive kolonisering eller infektion med multiresistente bakterier (MRB),
  2. syns- eller hørehandicap;
  3. psykiatrisk patologi, der kan forringe forståelsen;
  4. livstruende nødsituation;
  5. behov for stærkere smertestillende lægemidler (såsom Morfin, Ketamin og intranasale terapeutika).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Control group : standard multimodal stratgey

The child will be admitted to the emergency department.

If topical anesthesia (EMLA cream) is used for pain prevention, it will be applied to the skin prior to the procedure.

If analgesia with MEOPA (equimolar mixture of oxygen and nitrous oxide) is indicated, the child will inhale the gas via a mask during the procedure.

Non-pharmacological interventions, such as music therapy and/or watching cartoons, may also be used as part of standard care.

The procedure will begin with skin disinfection and identification of a suitable vein.

For the purposes of the study, the start of the procedure is defined as the moment the needle first penetrates the skin.

The procedure is considered complete once the needle is withdrawn and a dressing is applied.

Pharmacological interventions:

EMONO (Equimolar Mixture of Oxygen and Nitrous Oxide) EMLA cream (Eutectic Mixture of Local Anesthetics)

Non-pharmacological interventions:

Music therapy Audiovisual distraction (e.g., watching cartoons)

Eksperimentel: Experimental group: Standard multimodal pain management strategy supplemented by the PARO therapeuti

The child will be admitted to the emergency department.

If topical anesthesia (EMLA cream) is used to reduce pain, it will be applied to the skin 30 to 60 minutes prior to the procedure.

To facilitate familiarization with the PARO therapeutic robot, the device will be placed on or next to the child's lap approximately 15 minutes before the start of the procedure.

If analgesia with MEOPA (equimolar mixture of oxygen and nitrous oxide) is indicated, a face mask delivering the gas will be applied to the child.

The procedure will begin with skin disinfection and identification of a suitable vein.

For study purposes, the start of the procedure is defined as the moment the needle first penetrates the skin.

The procedure will be considered complete once the needle is withdrawn and a dressing is applied.

The child will be admitted to the emergency department.

If topical anesthesia (EMLA cream) is used for pain prevention, it will be applied to the skin 30 to 60 minutes prior to the procedure.

To facilitate familiarization with the PARO therapeutic robot, the device will be placed on or next to the child's lap approximately 15 minutes before the start of the procedure.

If analgesia with MEOPA (equimolar mixture of oxygen and nitrous oxide) is indicated, a face mask delivering the gas will be applied to the child during the procedure.

The procedure will begin with skin disinfection and identification of a suitable vein.

For study purposes, the start of the procedure is defined as the moment the needle first penetrates the skin.

The procedure will be considered complete once the needle is withdrawn and a dressing is applied.

Andre navne:
  • PARO group

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
FLACC(Face-Legs-Activity-Cry-Consolability) -assessed procedural pain during peripheral intravenous catheterization
Tidsramme: periprocedural

The effectiveness of PARO in reducing procedural pain will be assessed using the FLACC (Face, Legs, Activity, Cry, Consolability) observational scale. The FLACC is a validated hetero-assessment tool for evaluating pain in children aged 12 months to 7 years, particularly in the context of acute postoperative pain and brief painful medical procedures.

This scale evaluates five behavioral domains: facial expression, leg movement, activity, crying, and consolability. Each item is scored from 0 to 2, resulting in a total score ranging from 0 to 10. A score of 0 indicates a relaxed and comfortable child, while scores of 7 to 10 indicate severe pain or significant distress. A score of ≥3 is commonly considered indicative of clinically relevant pain requiring analgesic intervention.

periprocedural

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Procedural distress assessed using the PRIC (Procedural Restraint Intensity in Children) scale during peripheral intravenous catheterization
Tidsramme: skin disinfection AND Skin penetration
Children's distress will be evaluated using the PRIC scale (Procedural Restraint Intensity in Children), which measures the intensity of restraint required during pediatric procedures as an indirect indicator of procedural distress. The scale is stratified into five levels, assessing both the degree of physical restraint applied and the child's behavioral response. A score ≥3 is considered clinically significant and should prompt reassessment of pain and/or anxiolytic management. The PRIC scale has been preliminarily validated in a cohort of 20 children aged 2 months to 13 years, showing acceptable metrological properties; however, further studies are ongoing to confirm its validity in real-life clinical settings, as no gold standard currently exists. Procedural distress will be assessed at two time points: during skin disinfection with identification of the puncture site, and at skin penetration. Results will be compared between groups
skin disinfection AND Skin penetration
Heart rate variability as an indicator of procedural pain during peripheral intravenous catheterization
Tidsramme: periprocedural

Heart rate variability may serve as an indirect indicator of pain intensity, reflecting autonomic (sympathetic and parasympathetic) responses to nociceptive stimulation. Heart rate is a recognized physiological marker of pain in infants and children and may increase by approximately 10 to 25 beats per minute during painful procedures.

In this study, heart rate will be used to assess the effect of PARO on procedural pain. It will be continuously monitored using standard clinical monitoring equipment. Measurements will be recorded at three time points: 15 minutes before the procedure, during PARO introduction (if applicable), and at the time of venipuncture. The primary analysis will focus on the change (delta) in heart rate between baseline (15 minutes before the procedure) and venipuncture. Comparisons will be made between study groups.

periprocedural
Number of attempts required for successful peripheral venous access
Tidsramme: During the procedure (up to 3 attempts)
The effectiveness of the procedure will also be assessed by the number of attempts required to establish peripheral venous access. An attempt is defined as each skin puncture attempt. For ethical reasons, a maximum of three attempts will be permitted; beyond this threshold, the procedure will be considered a failure and alternative management in the operating room will be proposed.
During the procedure (up to 3 attempts)
Assessment of parental satisfaction
Tidsramme: 15 minutes after the end of the procedure
Parental satisfaction will be evaluated using a structured questionnaire administered to parents following the procedure. The instrument includes four items rated on a Likert-type response scale.
15 minutes after the end of the procedure
Parental anxiety assessed using the State-Trait Anxiety Inventory (STAI)
Tidsramme: at the end of the procedure

Parental anxiety will be assessed using the State-Trait Anxiety Inventory (STAI). The STAI is a self-administered questionnaire consisting of 40 items divided into two subscales: the State Anxiety subscale (STAI Form Y-1), which assesses current anxiety levels, and the Trait Anxiety subscale (STAI Form Y-2), which assesses general predisposition to anxiety.

Each item is rated on a 4-point Likert scale, with scores ranging from 1 (low anxiety) to 4 (high anxiety).

at the end of the procedure
Failure of peripheral venous access after three attempts
Tidsramme: periprocedural
Failure of peripheral intravenous catheterization is defined as the inability to establish venous access after a maximum of three attempts, as previously defined, necessitating management by the anesthesia team.
periprocedural
Assessment of paramedical staff satisfaction
Tidsramme: 15 minutes after the end of the procedure.

Satisfaction of the paramedical team will be assessed using a dedicated questionnaire administered to all nursing staff involved in the study at the end of the trial. The questionnaire will be completed once by each participant and consists of four items rated on a Likert-type scale.

In addition, one or more debriefing meetings will be organized with the care team at study completion to gather qualitative feedback regarding their experience and perceptions of the intervention

15 minutes after the end of the procedure.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Barbara LE GALLO, MD, Hôpitaux pédiatrique Nice CHU Lenval

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

3. marts 2026

Primær færdiggørelse (Anslået)

30. september 2026

Studieafslutning (Anslået)

30. september 2026

Datoer for studieregistrering

Først indsendt

27. november 2025

Først indsendt, der opfyldte QC-kriterier

9. december 2025

Først opslået (Faktiske)

23. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. maj 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. maj 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • 24-HPNCL-05 PARO
  • 2025-A00617-42 (Anden identifikator: ANSM)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Smertebehandling

Kliniske forsøg med Non-pharmacological and standard pharmacological interventions.

Abonner